Graham Capital Management L.P. Invests $351,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Graham Capital Management L.P. acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,358 shares of the specialty pharmaceutical company's stock, valued at approximately $351,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after buying an additional 30,420 shares in the last quarter. Deep Track Capital LP grew its position in ANI Pharmaceuticals by 28.6% in the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after acquiring an additional 144,214 shares during the last quarter. Global Alpha Capital Management Ltd. raised its stake in ANI Pharmaceuticals by 16.4% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock worth $34,525,000 after acquiring an additional 88,100 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after acquiring an additional 10,440 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after purchasing an additional 3,774 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Trading Down 1.4%

Shares of ANIP stock traded down $0.84 on Thursday, hitting $58.24. The company had a trading volume of 22,447 shares, compared to its average volume of 299,475. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market cap of $1.26 billion, a P/E ratio of -105.85 and a beta of 0.56. The stock's 50-day moving average is $66.76 and its two-hundred day moving average is $60.79.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same quarter last year, the firm posted $0.82 earnings per share. The firm's revenue was up 43.4% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on ANIP. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a research note on Monday, April 21st. Guggenheim reiterated a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $80.13.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company's stock, valued at $4,131,164.80. This represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now directly owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,681 shares of company stock valued at $468,698 in the last three months. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.